

Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies

Jean-Christophe Antoine, Jean-François Mosnier, Léna Absi, Philippe Convers, Jérôme Honnorat, Daniel Michel

Abstract

Objective—When to suspect a paraneoplastic disorder is a puzzling problem that has not recently been studied in a large series of patients referred for peripheral neuropathy.

Methods—From 422 consecutive patients with peripheral neuropathy, 26 were analysed who concomitantly had carcinoma but no tumorous infiltration, drug toxicity, or cachexia. Their clinical, pathological, and electrophysiological data were analysed according to the presence of anti-onconeural antibodies, the latency between presentation and cancer diagnosis, and the incidence of carcinoma in the corresponding types of neuropathy of the population of 422 patients.

Results—Seven patients (group I) had anti-onconeural antibodies (six anti-Hu, one anti-CV2) and 19 did not (groups IIA and B). In group I, subacute sensory neuropathy (SSN) was the most frequent but other neuropathies including demyelinating neuropathies were present. Patients in group II A had a short latency (mean 7.88 months), and a rapidly and usually severe neuropathy which corresponded in 11/14 to an established inflammatory disorder including neuropathy with encephalomyelitis, mononeuritis multiplex, and acute or chronic inflammatory demyelinating polyneuropathy (CIDP). Patients in group IIB had a long latency (mean 8.4 years) and a very chronic disorder corresponding in four of five to an axonal non-inflammatory polyneuropathy. In this population, the incidence of carcinoma occurring with a short latency was 47% in sensory neuronopathy, 1.7% in Guillain-Barré syndrome, 10% in mononeuritis multiplex and CIDP, and 4.5% in axonal polyneuropathy.

Conclusions—Paraneoplastic neuropathies associated with carcinoma are heterogeneous disorders. Neuropathies occurring with a long latency with tumours probably resulted from a coincidental association. Neuropathies which occurred within a few years of the tumour evolved rapidly and corresponded mostly to inflammatory disorders. As dysimmune neuropathies are probably paraneoplastic in a limited number of cases, patients with these disorders should probably not be investigated systematically for

carcinoma in the absence of anti-onconeural antibodies, except when the neuropathy is associated with encephalomyelitis and probably with vasculitis. Questions remain concerning CIDP.

(J Neurol Neurosurg Psychiatry 1999;67:7-14)

Keywords: paraneoplastic neurological syndromes; peripheral neuropathy; Guillain-Barré syndrome; chronic inflammatory demyelinating neuropathy

Depending on diagnostic criteria, up to 50% of patients with carcinoma develop peripheral neuropathy.¹ Treatment toxicity, tumorous infiltration, metabolic disturbances, or terminal cachexia account for most cases.² Paraneoplastic neuropathies are rare and heterogeneous disorders.³ Some of them are part of complex syndromes involving simultaneously the central (CNS) and peripheral nervous systems (PNS), the most frequent of which is subacute sensory neuronopathy/paraneoplastic encephalomyelitis (SSN/PEM).⁴ This disorder, when occurring with small cell lung cancer, is almost invariably associated with anti-Hu antibodies.⁵ Paraneoplastic syndromes associated with the other known anti-onconeural antibodies often involve the PNS, but the neuropathies are less characterised.⁶⁻¹⁰ Although attention has been mainly focused on antibody positive cases, there also exist true paraneoplastic neuropathies and no known antibodies.¹¹ These cases are difficult to define because many of the previous reports did not use modern investigation methods,^{12 13} and most of the recent studies concern single or few cases so that it is difficult to know which type of neuropathy should be investigated for cancer. We have therefore performed a study on 26 patients selected from 422 consecutive patients with peripheral neuropathy who developed their neurological disorder in association with carcinomas. This led us to discuss the classification of these neuropathies, their links with tumours, and when to investigate a patient with peripheral neuropathy for carcinoma.

Material and methods

PATIENT SELECTION

The patients were selected from the data bank of 422 consecutive patients investigated for peripheral neuropathy in the Department of Neurology of the University Hospital of Saint-Etienne between 1987 and June 1998. Our Department is the referential centre for neurological diseases in an estimated population of

Department of Neurology
J-C Antoine
P Convers
D Michel

Department of Pathology, Hôpital de Bellevue, Saint-Etienne, France
J-F Mosnier

Laboratory of Immunology, Centre de Transfusion Sanguine, Saint-Etienne, France
L Absi

INSERM U-433, Lyon, France
J-C Antoine
J Honnorat

Service de Neurologie B, Hôpital Neurologique, Lyon, France
J Honnorat

Correspondence to: J-C Antoine, Service de Neurologie, Hôpital de Bellevue, Boulevard Pasteur, 42055 Saint-Etienne Cedex, France. Telephone 0033 4 77 42 78 05; fax 0033 4 77 42 05 43.

Received 4 August 1998 and in final form 5 January 1999
Accepted 8 January 1999

Table 1 Clinical data for the seven patients with anti-onconeural antibodies (group I). Delay indicates the interval between the onset of neurological symptoms and cancer diagnosis. In every case, the neuropathy preceded the discovery of the tumour. The revised Rankin score is used to estimate the maximal deficit reached by the patients

No	Sex/age	Delay (months)	Clinical manifestations	Rankin	Course	Electrophysiology
1	M/56	23	Sensory > motor symmetric in four limbs ataxia. Central nystagmus. Hearing loss. Pain. Depressed tendon reflexes	4	Progressive	Reduced or absent SAP. Normal SCV. Reduced MAP, normal MCV. Reduced interferential pattern
2	M/56	9	Sensory symmetric in four limbs. Pain. Ataxia. Depressed tendon reflexes nystagmus, temporal lobe epilepsy	4	Progressive	Reduced SAP. Significantly reduced SCV (3.4µV and 29 m/s in ulnar nerves). Almost normal MCV
3	M/61	8	Sensory > motor deficit asymmetric in lower limbs. Areflexia. Pain. Digestive obstruction	3	Subacute	Absent SAP. Mildly reduced MCV in lower limbs with TD. Reduced interferential pattern
4	M/73	8	Sensory > motor asymmetric in lower limbs. Areflexia. Cerebellar ataxia	3	Subacute	Absent SAP. Mildly reduced SCV. Mild reduction of MAP and MCV reduced interferential pattern
5	M/50	2	Multifocal sensory and painful. Reduced tendon reflex. Orthostatic hypotension	2	Subacute	Absent or reduced SAP. Normal SCV normal MCV. Normal electromyography
6	M/65	8	Asymmetric sensory > motor deficit in four limbs. Pain. Ataxia. Memory loss	4	Progressive	Reduced or absent SAP. Mildly reduced MAP and MCV. Prolonged F waves. Temporal dispersion in tibial nerves
7	F/62	12	Sensory-motor deficit and areflexia in lower limbs. Cerebellar ataxia orthostatic hypotension	4	Progressive	Reduced SAP and SCV. Reduced MAP. Mildly reduced MCV. Reduced interferential pattern

Course corresponds to the onset of neurological symptoms: acute, <1 month; subacute 1-2 months; progressive, >2 months; CSF=number of lymphocytes/mm³; ND=not done; SCLC=small cell lung carcinoma; SAP=sensory action potential; SCV=sensory conduction velocities; MAP=motor action potentials; MCV= motor conduction velocities.

500 000 inhabitants. The selection criteria for the study were the presence of a clinically overt peripheral neuropathy, occurrence of a carcinoma proved by pathology or probable from radiological data, the simultaneous presence, at least at one time during the course, of both the neurological syndrome and the tumour, the absence of tumour infiltration, treatment toxicity, cachexia, or other known causes of peripheral neuropathy, and the availability of a serum sample for the research of anti-onconeural antibodies. The erythrocyte sedimentation rate, blood cell count, ionogram, blood glucose concentration, serum protein immunoelectrophoresis, and concentrations of creatinine, TSH, ANA, cholesterol, Apo A and B, vitamin B₁₂, and folate were at least determined. Cytological examination of the CSF was performed after cytocentrifugation and showed the absence of tumour cells. The course was considered as being acute when the maximal deficit was reached within 1 month, subacute within 2 months, chronic when longer than 2 months, and relapsing when relapses occurred spontaneously and independently from immunosuppressive treatments. The motor deficit was graded using the Medical Research Council scale and the disability by the modified Rankin score.¹⁴ Follow up was defined by the latency between the onset of the neuropathy and the last consultation. In addition, after reviewing the data of the 422 patients with peripheral neuropathy, we estimated the incidence of carcinoma in different types of neuropathy in comparison with published series.

ELECTROPHYSIOLOGICAL STUDY

Needle examination was performed and sensory and motor conduction velocities measured in the upper and lower limbs, using the methods described by Kimura *et al.*¹⁵ Routinely, the median and ulnar nerves were stimulated at the elbow and wrist, and the tibial and peroneal nerves at the knee and ankle. When a demyelinating process was suspected,

the median and ulnar nerves were also studied after stimulation at the Erb point and the axilla. The electrophysiological data were considered as indicative of a primary demyelinating neuropathy when they fulfilled the criteria established by the ad hoc subcommittee for the diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP).¹⁶ A significant reduction with normal duration of the sensory and motor action potentials (SAPs and MAPs), and slowing of conduction velocities not exceeding 80% of the lower limit of normal were considered as indicative of an axonal neuropathy. A neuronopathy (involvement of motor neurons in anterior horn or sensory ganglionopathy) was suspected when a significant reduction with normal duration of the SAP or MAP, and normal conduction velocities occurred. In addition, needle EMG evidence of fibrillation potentials, positive sharp waves, or fasciculations were required for the diagnosis of motor neuron involvement.

NEUROPATHOLOGICAL STUDY

Samples of superficial peroneal nerve biopsies (18 cases) were fixed in 10% formalin, embedded in paraffin, and stained with haematoxylin and eosin. Others were fixed in 2.5% glutaraldehyde, then in osmium tetroxide for semithin and ultrathin sections and for teased fibre examination. Muscle biopsies (six cases) were processed for paraffin, semithin, and ultrathin sections as nerve biopsies. For postmortem examination (four cases), the brain, spinal cord, certain lumbar sensory ganglia, and samples of peripheral nerves and muscles were fixed in 10% formalin; in addition, the L5 sensory ganglion and samples of the left L5 ventral and dorsal roots, sciatic nerve, and common peroneal nerve at the level of the knee were removed and processed as for nerve biopsy.

SCREENING FOR ANTI-ONCONEURAL ANTIBODIES

A serum sample was obtained from each patient and stored at -80°C until required.

Table 1 continued

CSF	Tumour	Pathology	Antibody
2.0 g/l 54 lympho	SCLC	Nerve biopsy, fibre loss, axonal degeneration	Anti-Hu
1.14 g/l 43 lympho	SCLC	Nerve biopsy, fibre loss, axonal degeneration	Anti-Hu
0.42 g/l 1 lympho	SCLC	Nerve biopsy, fibre loss	Anti-Hu
0.78 g/l 1 lympho	Small cell carcinoma prostate	Nerve biopsy, axonal degeneration	Anti-Hu
1.2 g/l 1 lympho	SCLC	ND	Anti-Hu
1.62 g/l 52 lympho	SCLC	Necropsy: mild ganglionitis, fibre loss in distal nerves. Demyelination, onion bulbs endoneurial lymphocytes	Anti-Hu
0.77 g/l 17 lympho	Undifferentiated carcinoma mediastinum	Necropsy: normal sensory ganglia and spinal cord. Fibre loss demyelinated fibers	Anti-CV2

Screening for anti-onconeural antiantibodies (anti-Hu, anti-Ri, anti-Yo, anti-amphiphysin, and anti-CV2) was performed by immunohistochemistry and western blotting experiments on rat brain in accordance with the guidelines recommended for their detection,¹⁷ using paraformaldehyde fixed sections of rat cerebellum, as described elsewhere.⁹ Positivity for anti-onconeural antibodies was confirmed by western blotting using the recombinant HuD, CDR 62 proteins kindly provided by Dr J Dalmau (Sloan-Kettering Cancer Center, New York, USA), and the recombinant amphiphysin protein kindly provided by Professor P DeCamilli (Yale University, New Haven, USA) and for anti-CV2 antibodies with an S3 subcellular fraction of new born rat brain proteins.⁹

Results

Twenty six patients were selected for the study. None of them, except patient 17, had received chemotherapy before the onset of the neuropathy but the disorder (demyelinating Guillain-Barré syndrome) was not consistent with drug toxicity. Results from four of these patients have been published in full detail elsewhere.^{18,19} Seven patients had anti-onconeural antibodies (group I) and 19 did not (group II). Except in group I, the patients were not systematically investigated for cancer and the tumours were diagnosed when clinically apparent.

GROUP I: PATIENTS WITH ANTI-ONCONEURAL ANTIBODIES (SEVEN PATIENTS)

The neuropathy preceded the discovery of the cancer by 2 to 23 months (mean 10.00 months, table 1) and was usually severely disabling (Rankin score at 3 or 4 in six of seven patients) within a few months. Patients 1 to 6 had anti-Hu antibodies and small cell carcinoma of lung or prostate. Patient 7 had mediastinal undifferentiated carcinoma and anti-CV2 antibodies which reacted with a unc-33 related and developmentally regulated protein.^{9,20-22} Pa-

tients with anti-Hu antibodies had a subacute or rapidly progressive neuropathy that was sensory in two and sensory-motor but predominantly sensory in four. Symptoms of PEM were present in four of six. Two patients had dysautonomy. The sensory neuropathy had the clinical and electrophysiological characteristics of SSN in five of six cases. The last patient had a significant reduction of SCV (below 70% of lower limits of normal) with mild reduction of SAP. The study of motor conduction velocities (MCVs) was consistent with a mild axonal neuropathy in half of the cases. Electromyographic indications of a motor neuron disorder were never seen even when motor deficit was present. Two patients had additional unusual features suggestive of a mildly demyelinating neuropathy superimposed on the sensory neuropathy. This was confirmed by necropsy in one of them.¹⁹ In the other patients, nerve biopsy showed fibre loss and Wallerian degeneration without inflammatory changes. The patient with anti-CV2 antibodies had a mild sensory-motor neuropathy and cerebellar ataxia. Electrophysiology was consistent with an axonal neuropathy. At necropsy, dorsal root ganglia and anterior horns were normal. In the nerves, fibre loss was present and some fibres were undergoing axonal degeneration. Other fibres had a thin myelin sheath and some were undergoing demyelination. Inflammatory changes were absent. None of the patients in group I improved with steroids, plasma exchanges, or intravenous immunoglobulins.

GROUP II: PATIENTS WITHOUT ANTI-ONCONEURAL ANTIBODIES (19 PATIENTS)

The characteristics of the neuropathy and the associated cancers are summarised in tables 2 and 3. Patients in this group had very different types of carcinoma. The neuropathies were heterogeneous and can be divided into four types.

(1) In four patients (8–11), a sensory or sensory-motor neuropathy was associated with signs of corticospinal involvement suggesting that PEM was present. This was confirmed by postmortem examination in cases 8 and 9. Electrophysiology was axonal (9 and 10) or neuronal (8 and 11). Inflammatory changes were present in the CSF of three of four of these patients. In the peripheral nerves, biopsies or necropsies showed fibre loss and Wallerian degeneration. Lesions were marked in patients 8, 10, and 11, and mild in patient 9. Mononuclear cell infiltrates were present in the endoneurium and around epineurial vessels in patients 8 and 11.

(2) In two patients (12 and 13), the neuropathy presented as mononeuropathy multiplex (MNM) with systemic or nerve restricted non-necrotising vasculitis. Patient 13 had orthostatic hypotension.

(3) Seven patients (patients 14 to 16 and 22 to 25) had a sensory motor neuropathy that was electrophysiologically axonal. Nerve biopsy performed in three showed chronic axonal neuropathy without inflammatory changes. In the others, who did not have a pathological study, the possibility of metastatic involvement

Table 2 Clinical data for the 14 patients with a short delay between the onset of the neuropathy and the discovery of the tumour who had no anti-onconeural antibodies (group IIA). Delay indicates the interval between the onset of neurological symptoms and cancer diagnosis and is expressed in months (m) or weeks (w). In every case, except case 13, the neuropathy preceded the discovery of the tumour. The revised Rankin score is used to estimate the maximal deficit reached by the patients

No	Sex/age	Delay	Clinical manifestations	Course	Rankin	Electro-physiology	GSF	Tumour	Pathological study	Treatments (neuropathy)
8	M/65	3 m	Proximal and distal sensory motor deficit, pain in four limbs, diffuse areflexia, amyotrophy. Respiratory deficiency. Left Babinski	Subacute	5	Neuronal	1.12 g/l 11 lympho	Lung (CT)	Inflammatory ganglionitis and myelitis, preservation of motor neurons, inflammatory lesions in the nerves, necrotising myopathy	No improvement steroids PE and IgIV
9	F/71	26 m	Pain, paresthesia, proximal > distal motor deficit in four limbs. Lower limbs areflexia. Bilateral Babinski. Reticular livedo	Progressive	4	Axonal	0.3 g/l 1 lympho	Pancreas adenocarcinoma	Mild inflammatory ganglionitis and axonal neuropathy, vessel thickening, inflammatory myositis	No improvement steroids
10	M/73	26 m	Severe sensory > motor deficit in four limbs lower limbs areflexia, transient diplopia bilateral Babinski	Progressive	4	Axonal	1.20 g/l 35 lympho	SCLC lung	Nerve biopsy: fibre loss, axonal degeneration, slight inflammatory reaction, normal muscle	No improvement steroids PE azat
11	M/74	4 m	Sensory motor proximal and distal deficit in four limbs, amyotrophy, normal tendon reflexes, bilateral Babinski	Progressive	4	Neuronal	2.02 g/l 28 lympho	Urinary (CT)	Nerve biopsy: multifocal axonal lesions, endoneurial inflammatory reaction vasculitis. Muscle: neurogenic atrophy	No improvement steroids
12	F/72	6 m	Mononeuropathy multiplex. Peroneal and tibial nerves hyper eosinophilia, raised ESR, sinusitis	Acute	3	Axonal	0.32 g/l 1 lympho	Colon adenocarcinoma (recidive)	Nerve biopsy: axonal degeneration, vasculitis in a nasal polypoid formation. Muscle: neurogenic atrophy	Improvement steroids (Rankin 3 to 1)
13	M/65	2 w	Multifocal sensory motor deficit in right arm and lower limbs. Leg areflexia. Orthostatic hypotension	Relapsing	2	Axonal	0.50 g/l 1 lympho	Tongue epidermoid	Nerve biopsy: fibre loss, degenerating fibres, epineurial vasculitis	Spontaneous improvement
14	M/84	7 m	Distal sensory painful asymmetric in four limbs, lower limb areflexia	Subacute	3	Axonal	0.49 g/l 1 lympho	Lung undifferentiated adenocarcinoma	ND	No improvement steroids
15	M/85	9 m	Distal pain, sensory loss and areflexia in lower limbs	Progressive	2	Axonal	0.53 g/l 1 lympho	Lung (CT scan)	ND	ND
16	M/61	1 m	Motor>sensory asymmetric deficit in four limbs, fasciculations, absent or reduced tendon reflexes	Acute	3	Neuronal	0.30 g/l 1 lympho	Gastric adenocarcinoma	Neurogenic atrophy in muscle	No improvement steroids
17	M/48	0 m	Sensory motor Guillain-Barré syndrome, areflexia in four limbs, facial nerve palsy	Acute	4	Demyelinating	0.66 g/l 1 lympho	Tongue epidermoid (recidive)	Nerve biopsy: ongoing macrophage induced demyelination	Improvement IgIV (Rankin 4 to 2)
18	M/73	3 m	CIDP. Sensory motor mainly proximal deficit and areflexia in four limbs	Progressive	3	Demyelinating	1.27 g/l 1 lympho	Pancreas adenocarcinoma	ND	Improvement IgIV (Rankin 3 to 2)
19	M/73	6 m	CIDP. Sensory motor mainly proximal mainly upper limbs deficit and areflexia in four limbs	Progressive	2	Demyelinating	0.90 g/l 1 lympho	Colon adenocarcinoma	Nerve biopsy: fiber loss, remyelinated fibers, onion bulb formations, slight inflammatory changes	Improvement after surgery (Rankin 2 to 1)
20	M/61	9 m	CIDP. Mainly motor proximal>distal deficit and areflexia in four limbs	Progressive	4	Demyelinating	1.60 g/l 1 lympho	Liver adenocarcinoma	Nerve biopsy: almost normal fibers endoneurial lymphocytes	Improvement steroid IgIV azat (Rankin 4 to 1)
21	M/78	+ 2 m	Sensory motor proximal and distal deficit in four limbs. Depressed or abolished tendon reflexes	Subacute	5	Demyelinating	1.60 g/l 1 + axonal lympho	Prostate adenocarcinoma	Demyelinated fibers, slight onion bulbs degenerated fibers and regenerating clusters endoneurial macrophages	Improvement steroids (Rankin 5 to 4)

Course corresponds to the onset of neurological symptoms: acute, <1 month; subacute 1-2 months; progressive, >2 months.. CIDP=chronic inflammatory demyelinating polyneuropathy; TD=temporal dispersion; CB= conduction block. PE=plasma exchanges. IgIV=intravenous immunoglobulins. azat=azathioprine. When improvement occurred after immunotherapy, the Rankin score before and after treatment is given in parentheses. Other abbreviations are the same as in table 1

Table 3 Clinical data for the five patients with a long delay between the onset of the neuropathy and the discovery of the tumour who had no anti-onconeural antibodies (group IIB)

No	Sex/age	Delay (y)	Clinical manifestations	Course	Rankin	Electrophysiology	CSF	Tumour	Pathological study
22	2M/73	5	Sensory loss in lower limbs, lower limbs areflexia	Progressive	2	Axonal, reduced/absent SAP, reduced MAP, mild reduction of CV	0.8 g/l 1 lympho	Prostate adenocarcinoma	Nerve biopsy: fibre loss, no inflammatory changes
23	F/71	9	Pain, paresthesia, sensory loss and areflexia in lower limbs	Progressive	1	Axonal, reduced MAP/SAP. Mild reduction of CV	0.2 g/l 1 lympho	Pancreas adenocarcinoma	Fibre loss, regenerating clusters, no inflammatory changes
24	M/72	4-5	Distal sensory motor deficit and areflexia in lower limbs	Progressive	2	Axonal, reduced/absent SAP and MAP, mild reduction M-S CV	0.67 g/l 1 lympho	Penis epithelioma	Nerve biopsy: severe fibre loss, no inflammatory changes
25	M/64	14	Sensory motor distal deficit and areflexia in lower limbs	Progressive	2	Axonal, reduced MAP/SAP, mild reduction of CV	0.7 g/l 1 lympho	Prostate adenocarcinoma	ND
26	M/64	10	CIDP. Mild paraesthesia and motor deficit, hyporeflexia in four limbs. Hypertrophic nerves. MGUS IgG	Progressive	1	Demyelinating severely reduced MCV, temporal dispersion	8.2 g/l 1 lympho	Malignant melanoma	Nerve biopsy: demyelinated fibres, onion bulb formations

Abbreviations are the same as in table 2. In all cases, the neuropathy preceded the diagnosis of cancer.

of peripheral nerves was low as CSF examination showed no tumour cells and patients were followed up several months or years after tumour diagnosis with stabilisation of the neuropathy.

(4) Six patients (patients 17 to 21 and 26) had an electrophysiological demyelinating neuropathy. In patient 17, it was a typical Guillain-Barré syndrome that occurred simultaneously with a rapidly lethal (within 3 months) recurrence of tongue carcinoma. The other patients had a CIDP-like neuropathy which conformed to the diagnostic criteria of the ad hoc subcommittee.¹⁸ Patient 21 had mixed axonal and demyelinating features on electrophysiology. Nerve biopsy showed fibre loss, regenerating clusters suggesting distal axonal degeneration, and demyelinated fibres, onion bulb formations, and endoneurial macrophages.

TYPE OF NEUROPATHY ACCORDING TO DELAY IN GROUP II

Patients in group II can be subdivided into two groups according to the delay between the onset of the neuropathy and the diagnosis of cancer. Group IIA consisted of 14 patients (table 2) in whom the delay was between 0–26, mean 7.88 months. They usually had a severe neuropathy (Rankin score 2–5, mean 3.4) with either acute, subacute, progressive, or relapsing course. When progressive, the maximal disability was reached within 6 to 9 months. The neuropathy was sensory-motor in 12 of 14 patients and purely sensory in two. None of them had sensory ataxia. In 11 of 14 patients, the neuropathy corresponded to an established inflammatory disorder (SSN/EM, mononeuritis multiplex, Guillain-Barré syndrome, or CIDP). Immunosuppressive treatments were performed in 11 patients. Patients with CIDP or Guillain-Barré syndrome, and one patient with MNM improved. None of the patients with CNS involvement or non-specific axonal neuropathy improved. Group IIB (table 3) consisted of five patients in whom the delay varied from 4 to 14 (mean 8.4). years In all of them, the neuropathy was very slowly progressive and evolved over many years. The disability

was minor (Rankin score 1 or 2). Four of these five patients had an axonal sensory motor polyneuropathy without inflammatory changes. The last patient had a very chronic and indolent CIDP. After 10 years, he developed malignant melanoma. He had no vitiligo and the research for anti-GM1, GD2, GD3, GM3, GD1a, and GD1b antibodies was negative.

INCIDENCE OF CARCINOMA ACCORDING TO THE TYPE OF NEUROPATHY

The 26 patients reported above represent 6.2% of the patients referred for the diagnosis of neuropathy and 9% of patients over 50 years of age. However, when taking into account only patients in whom the tumour appeared within 2.5 years, the distribution was different according to the type of neuropathy. Among our patients with sensory neuronopathy, 47% had a carcinoma. These patients usually had a subacute or rapidly progressive disorder with symptoms of PEM while patients without cancer had an isolated and slowly progressive neuropathy. Comparatively, one patient among 59 with Guillain-Barré syndrome (1.7%) had carcinoma simultaneously. Patients with CIDP or mononeuritis multiplex, had almost the same incidence of carcinoma (10%) and it was 4.5% in patients with axonal sensory-motor polyneuropathy of otherwise unknown origin.

Discussion

Contrary to studies originating from cancer centres,³ our population of patients was first referred to a department of neurology. This can explain why in our series, the neurological disorder usually preceded the diagnosis of tumour. None of the patients selected for the present study had cachexia, tumorous infiltration, or chemotherapy as the cause of the neuropathy suggesting that their disorders were paraneoplastic. Currently, the detection of high titres of one of the anti-onconeural antibodies is the best way to identify a neurological syndrome as paraneoplastic. We found one of them (mainly anti-Hu antibodies) in 28% of patients (group I) only. These patients had a subacute or rapidly progressive and usually

severely disabling neurological disorder involving both the CNS and PNS in most of them. Although most patients with anti-Hu antibodies had SSN,²³ we also found axonal or demyelinating neuropathies in accordance with recent studies which indicate that neuropathies associated anti-Hu antibodies can be heterogeneous.²⁴⁻²⁷

In 19 of 26 patients, anti-onconeural antibodies were not detected. The neuropathies in this group (group II) were also heterogeneous, including neuropathy with encephelomyelitis, mononeuropathy multiplex, Guillain-Barré syndrome, CIDP, and axonal polyneuropathy. Although individual cases or small series of each of these disorders have been reported to depend on a remote effect of cancer,²⁸⁻³¹ their paraneoplastic origin cannot be ascertained except when the neuropathy is associated with encephalomyelitis.⁵ In the absence of specific markers, arguments in favour of a remote effect of carcinoma can only be drawn from indirect criteria. In our study, we used (1) the latency between onset of the neuropathy and diagnosis of cancer, (2) the characteristics of the neuropathy, and (3) the incidence of cancer in the corresponding type of neuropathy.

In Lambert-Eaton myasthenic syndrome, the risk of cancer decreases sharply after 2 years and becomes extremely low at 4 years³² showing that when a disorder is paraneoplastic, cancer becomes apparent within a relatively short delay. In our series, we clearly have two groups of patients. In the first (group IIA), the latency was short and comparable with that of patients with paraneoplastic antibodies^{6 23 27} suggesting direct physiopathological links between tumour and neuropathy. In the second (group IIB), carcinoma appeared many years after the onset of the neuropathy, suggesting that it was a coincidental association. The number of patients in this group was relatively small but as protracted follow up over more than 5 years was obtained in a small proportion

of our population only, several cases may have been missed in group IIB. Conversely, as most of our patients were followed up during the first years of the evolution of their neuropathy only a few patients had probably escaped in group IIA.

The characteristics of the neuropathies were different between group II A and B. Patients in group IIB had a very chronic, slowly progressive, and mildly disabling disorder as opposed to group IIA in which the neuropathies had a severe and rapid course. Interestingly, 78% of the neuropathies in group IIA correspond to a known inflammatory disorder of the PNS. This contrasts with patients with long latency who for the most part had a non-inflammatory axonal polyneuropathy. Only one of them developed an indolent CIDP which evolved over 10 years before the diagnosis of malignant melanoma. Recently, a particular association of CIDP and melanoma has been reported, possibly involving a shared immunoreactivity against gangliosides.³³ However, our patient had no antiganglioside antibodies and differed from these cases by the delay of tumour diagnosis and the absence of vitiligo.

The pathophysiology of paraneoplastic neurological syndrome is not completely understood, but an increasing amount of data indicates that at least in patients with anti-onconeural antibodies dysimmune mechanisms are involved.⁵ The fact that in our series most of the neuropathies which occurred within 2.5 years with a carcinoma correspond to known inflammatory disorders suggests that despite the absence of specific antibodies or other known immunological markers, tumours have in some way induced the immunological perturbations underlying the neuropathies.

Each of the well established paraneoplastic neurological syndromes also occurs without cancer. Thus, 40% of patients with Lambert-Eaton myasthenic syndrome do not have tumours.³² The proportion is 50% in patients

Table 4 Incidence of carcinoma according to the type of neuropathy in our series and in several other published series

Type of neuropathy (authors)	Number of cases	Incidence of carcinoma (%)	Follow up (mean value in our study)	Commentaries
General population of neuropathies				
Prineas <i>et al</i> ⁸⁵	278	5.4	>18 months	
Our study	422	6.2	ND	
Guillain-Barré syndrome				
Halls <i>et al</i> ²⁶	29	6.9	>400 days	
Italian study group ³⁷	297	0.7	24 months	% of death due to carcinoma within 250 days
Our study*	59	1.7	<2 y	
CIDP				
Barhon <i>et al</i> ⁸⁸	60	5.0	NS	These studies include patients with MGUS of unknown reactivity
Gorson <i>et al</i> ⁸⁹	67	0	Mean 3 y	
Our study*	38	10.5	5.7 y (0.5-16)	
Vasculitis/mononeuritis multiplex				
Vincent <i>et al</i> ¹⁰	50	14	NS	Patients selected from nerve biopsies
Vincent <i>et al</i> ¹¹	50	10	NS	
Harati <i>et al</i> ¹²	33	9	Mean 18.5 months	
Our study*	20	10	2.3 y (0.5-10)	
Axonal polyneuropathy of otherwise undetermined cause				
Fagius <i>et al</i> ¹³	91	1.0	Mean 3.7 y	
McLeod <i>et al</i> ¹⁴	47	10.6	Median 3 y	
Notermans <i>et al</i> ¹⁵	75	5.3	4.7 y	Prospective study
Camerlingo <i>et al</i> ¹⁶	51	29.4	Mean 51.4 months	Prospective study of patients with pure sensory neuropathy
Our study*	67	10.3	3.7 y (0.3-11)	4.5% within 2 years after onset

ND=not done; NS=not stated; MGUS=monoclonal gammopathy of unknown significance.

* Patients with a short latency are taken into account only.

with subacute sensory neuropathy⁵ and around 80% in patients with dermatomyositis and polymyositis.³⁴ In our series, 9% of patients over 50 years of age with neuropathy developed carcinoma. There are only a few studies considering the problem of the incidence of carcinoma in peripheral neuropathy (see table 4),³⁵⁻⁴⁶ particularly when they are devoted to one type of neuropathy as patients with tumour are often excluded from these studies. When combining their results with ours, 5% to 15% of patients with neuropathy seem to develop carcinoma. As expected, the highest incidence is found with sensory neuronopathy.^{5, 46} It is probably very low in Guillain-Barré syndrome and high (up to 15%) in vasculitic neuropathy. Due to a lack of studies, data are less clear with CIDP, but our results indicate an incidence of 10%. In patients with axonal polyneuropathy of otherwise unknown origin, only 4%-5% of patients develop cancer within the first years after the appearance of the neuropathy and an additional similar proportion with protracted follow up.

In conclusion, paraneoplastic neuropathies are heterogeneous disorders even in patients with anti-onconeural antibodies. In patients without antibodies, neuropathies which occurred within 2.5 years of carcinoma were probably paraneoplastic and corresponded mainly to inflammatory disorders whereas in neuropathies in which the cancer appeared after many years the association was probably coincidental. As dysimmune neuropathies are paraneoplastic in a limited number of cases, patients with these disorders should probably not be investigated systematically for carcinoma in the absence of anti-onconeural antibodies, except when the neuropathy is associated with encephalomyelitis and with vasculitis. Questions remain concerning CIDP.

We express our grateful thanks to Dr Josep Dalmau for reading the manuscript and giving useful criticism and advice.

- 1 McLeod JG. *Paraneoplastic neuropathies*. In: Dyck PJ, Thomas PK, eds. *Peripheral neuropathy*. Philadelphia: Saunders, 1993;II:1583-90.
- 2 Posner JB. *Neurologic complications of cancer*. Philadelphia: FA Davis, 1995.
- 3 Smitt PS, Posner JB. *Paraneoplastic peripheral neuropathy*. In: Latov N, Wokke JH, Kelly JJ, eds. *Immunological and infectious diseases of the peripheral nerves*. Cambridge: Cambridge University Press, 1998:208-24.
- 4 Henson RA, Urich H. *Peripheral neuropathy associated with malignant disease*. In: Vinken PJ, Bruyn GW, eds. *Handbook of clinical neurology*. Amsterdam: North-Holland, 1979;8: 131-48.
- 5 Dalmau J, Posner JB. Paraneoplastic syndromes affecting the nervous system. *Semin Oncol* 1997;24:318-28.
- 6 Peterson K, Rosenblum MK, Kotanides H, et al. Paraneoplastic cerebellar degeneration; a clinical analysis of 55 anti-Yo antibody-positive patients. *Neurology* 1992;42: 1931-7.
- 7 Konanc DA, O'Neil BP, Caselli RJ, et al. Peripheral neuropathic presentation in 3 patients with seropositivity for type 1 anti-Purkinje cell antibodies (PCA-1) and ovarian or related müllerian carcinoma. *Neurology* 1995;45(suppl 4):A320.
- 8 Hormingo A, Dalmau J, Rosenblum MK, et al. Immunological and pathological study of anti-Ri-associated encephalopathy. *Ann Neurol* 1994;36:896-902.
- 9 Honnorat J, Antoine JC, Derrington E, et al. Antibodies to a subpopulation of glial cells and a 66 kD developmental protein in patients with paraneoplastic neurological syndrome. *J Neurol Neurosurg Psychiatry* 1996;61:270-8.

- 10 Dropcho EJ. Antiampiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis. *Ann Neurol* 1996;39:659-67.
- 11 Graus F, René R. Paraneoplastic neuropathies. *Eur Neurol* 1993;33:279-86.
- 12 Henson RA, Russel DS, Wilkinson M. Carcinomatous neuropathy and myopathy. A clinical and pathological study. *Brain* 1954;77:82-120.
- 13 Croft PB, Urich H, Wilkinson M. Peripheral neuropathy of sensory motor type associated with malignant disease. *Brain* 1967;90:31-66.
- 14 Uchuya M, Graus F, Vega F, et al. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. *J Neurol Neurosurg Psychiatry* 1996;60:388-92.
- 15 Kimura J. *Electrodiagnosis in diseases of nerve and muscle: principles and practice*. Philadelphia: FA Davis, 1989.
- 16 Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). *Neurology* 1991;41:617-8.
- 17 Moll JWB, Antoine JC, Brashear HR, et al. Guidelines on the detection of paraneoplastic anti-neuronal antibodies. *Neurology* 1995;45:1937-41.
- 18 Antoine JC, Mosnier MF, Convers P, et al. Chronic inflammatory demyelinating polyneuropathy associated with carcinoma. *J Neurol Neurosurg Psychiatry* 1996;60:188-90.
- 19 Antoine JC, Mosnier JF, Honnorat J, et al. Paraneoplastic demyelinating neuropathy, subacute sensory neuronopathy and anti-Hu antibodies. Clinicopathological study of an autopsy case. *Muscle Nerve* 1998;21:850-7.
- 20 Antoine JC, Honnorat J, Vocanson C, et al. Posterior uveitis, paraneoplastic encephalomyelitis and auto-antibodies reacting with a developmental protein of brain and retina. *J Neurol Sci* 1993;117:215-23.
- 21 Quash TT, Rong Y, Belin MF, et al. Molecular cloning of a new unc-33 like c-DNA from rat brain and its relation to paraneoplastic neurological syndromes. *Molecular Brain Research* 1997;46:329-32.
- 22 Honnorat J, Aguera M, Zalc B, et al. POP66. A paraneoplastic encephalomyelitis-related antigen, is a marker of adult oligodendrocytes. *J Neuropathol Exp Neurol* 1998;57:311-22.
- 23 Dalmau J, Graus F, Rosenblum MK, et al. Anti-Hu associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. *Medicine* 1992;71:59-72.
- 24 Younger DS, Dalmau J, Inghirami G, et al. Anti-Hu-associated peripheral nerve and muscle microvasculitis. *Neurology* 1994;44:181-2.
- 25 Oh SDI, Dropcho EJ, Claussen GC. Anti-Hu associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature. *Muscle Nerve* 1997;20:1576-82.
- 26 Eggert C, Hagel C, Pfeiffer G. Anti-Hu associated paraneoplastic sensory neuropathy with peripheral nerve demyelination and microvasculitis. *J Neurol Sciences* 1998;155:178-81.
- 27 Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. *Neurology* 1998;50: 652-7.
- 28 Oh SDI, Slaughter R, Harlem L. Paraneoplastic vasculitic neuropathy: a treatable neuropathy. *Muscle Nerve* 1991;14: 152-6.
- 29 Rae Grant AD, Feasby TE, Brown XF, et al. A reversible demyelinating polyradiculoneuropathy associated with cancer. *Neurology* 1986;36(suppl 1):81.
- 30 Peterson K, Forsyth PA, Posner JB. Paraneoplastic sensorimotor neuropathy associated with breast cancer. *J Neurooncol* 1994;21:159-70.
- 31 Yamada M, Shintani S, Mitani K, et al. Peripheral neuropathy with predominantly motor manifestations in a patient with carcinoma of the uterus. *J Neurol* 1988;235: 368-70.
- 32 O'Neil JH, Murray NMF, Newsom-Davis J. The Lambert Eaton myasthenic syndrome. A review of 50 cases. *Brain* 1988;111:577-96.
- 33 Bird SDI, Brown MJ, Shy ME, et al. Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma. *Neurology* 1996;46:822-4.
- 34 Engel AG, Hohlfeld R, Baker BQ. Inflammatory myopathies. In: Engel AG, Franzini-Armstrong C, eds. *Myology*. New York: McGraw-Hill, 1994; II:1335-83.
- 35 Prineas J. Polyneuropathies of undetermined cause. *Acta Neurol Scand* 1970;46(suppl 44):1-72.
- 36 Halls J, Bredkjaer C, Friis ML. Guillain-Barre syndrome: diagnostic criteria, epidemiology, clinical course and prognosis. *Acta Neurol Scand* 1988;78:118-22.
- 37 The Italian Guillain-Barré Study Group. The prognosis and main prognostic indicators of Guillain-Barré syndrome. A multicentre prospective study of 297 patients. *Brain* 1996; 119:2053-61.
- 38 Barhon RJ, Kissel JT, Warmolts JR, et al. Chronic inflammatory demyelinating polyneuropathy. Clinical characteristics, course, and recommendations for diagnosis criteria. *Arch Neurol* 1989;46:878-84.
- 39 Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy; clinical features and response to treatment in 67 consecutive patients with and without a monoclonal neuropathy. *Neurology* 1997;48:321-8.

- 40 Vincent D, Dubas F, Haw JJ, et al. Microvasculites nerveuses et musculaires: 50 cases. *Rev Neurol* 1985;141:440-6.
- 41 Vincent D, Dubas F, Haw JJ, et al. Nerve and muscle microvasculitis. *J Neurol Neurosurg Psychiatry* 1986;49:1007-10.
- 42 Harati Y Niakan E. The clinical spectrum of inflammatory-angiopathic neuropathy. *J Neurol Neurosurg Psychiatry* 1986;49:1313-16.
- 43 Fagius J. Chronic cryptogenic polyneuropathy. The search for a cause. *Acta Neurol Scand* 1983;67:173-80.
- 44 McLeod JG, Tuck RR, Pollard JD, et al. Chronic polyneuropathy of undetermined cause. *J Neurol Neurosurg Psychiatry* 1984;47:530-5.
- 45 Notermans NC, Wokke JHJ, van der Graaf Y, et al. Chronic idiopathic axonal polyneuropathy: a five year follow up. *J Neurol Neurosurg Psychiatry* 1994;57:1525-7.
- 46 Camerlingo M, Nemni R, Ferraro B, et al. Malignancy and sensory neuropathy of unexplained cause. A prospective study of 51 patients. *Arch Neurol* 1998;55:981-4.

NEUROLOGICAL STAMP

Armauer Gerhard Henrik Hansen (1841-1912)

Armauer Hansen of Bergen, the leading authority of his time on leprosy, first identified the leprosy bacillus in Norway where the disease was endemic. Leprosy had been thought to be a hereditary affliction. Hansen concluded from epidemiological studies that it was infectious and that the rod shaped bacilli he observed (in 1873) were the cause of leprosy. His claim was not acknowledged for many years. Hansen never managed to fulfil the postulates of Robert Koch and transmit the disease to animals or men using the bacilli. This difficulty was also met with by later workers. Hansen was forced to resign from the Bergen Leprosy Hospital in 1880 after injudiciously injecting live leprosy bacilli into a patient without first obtaining her permission. Nevertheless, he carried on with his own research. By implementing a policy of limited isolation he succeeded in reducing the Norwegian incidence of leprosy from 2833 cases in 1850 to 140 in 1923. He was honoured philatelically by France in 1973 on the centenary of the identification of the leprosy bacillus (Stanley Gibbons 2013, Scott 1379).

L F HAAS

